Status:
ACTIVE_NOT_RECRUITING
Registry Platform Colorectal Cancer
Lead Sponsor:
iOMEDICO AG
Conditions:
Colorectal Cancer Metastatic
Eligibility:
All Genders
18+ years
Brief Summary
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic colorectal cancer, treated in palliative intention in daily routine practice in Germany...
Detailed Description
AZURITE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic...
Eligibility Criteria
Inclusion
- Patients with histologically proven metastatic colorectal cancer (stage IV) at time of inclusion (patients with metastatic disease and potential curative treatment intention are allowed)
- Age ≥ 18 years
- Planned first systemic therapy for metastatic disease
- Signed and dated informed consent form
- Patients participating in the PRO module: prior to or at start of first systemic treatment for mCRC
- Patients not participating in the PRO module: within four weeks after start of fist systemic therapy for mCRC
Exclusion
- Patient who do not receive any systemic therapy for mCRC
- Patients whose metastatic disease was surgically resected prior to inclusion and who start adjuvant chemotherapy
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04867525
Start Date
May 1 2021
End Date
April 1 2026
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple sites all over germany
Multiple Locations, Germany